35 results about "Stem Cell Self-Renewal" patented technology

The present invention generally provides a means to control stem cell self-renewal and differentiation. More particularly, the current invention is directed toward the elucidation of a signal transduction pathway that controls the expression of a gene necessary for differentiation of stem daughter cells. By modulating the levels of key regulatory molecules within this pathway, the fate of stem cell self-renewal and differentiation may be controlled. In addition, the present invention also provides mutant organisms, tissues, cells, as well methods where the level of key molecules within the pathway are modulated.

The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.

Manipulation of the circadian clock system by providing suitable cells with the circadian clock system under conditions that effectively control myeloid cell development, stem cell self-renewal, differentiation and / or function, and clock-controlled gene expression with E-box sequences in the regulatory region , A method for controlling bone marrow cell development, stem cell self-renewal, differentiation and / or function, and a clock with an E-box sequence in the regulatory region to control gene expression. Additionally, in vitro engineered tissues are disclosed that include a plurality of cells or cell types in intimate contact with each other to form the tissue, these cells or cell types having properties that have been modulated to regulate the growth, development and and / or functional rhythmic clock system.

The present invention provides a method for inducing amplified human bone marrow mesenchymal stem cells in vitro to directionally differentiate into cardiac cells. According to the present invention, by using the biological characteristics of MSCs, human MSCs are isolated and enriched by the density gradient centrifugation method, and stem cells are amplified to obtain a large number of stem cells by using stem cell self-renewal and proliferation characteristics. The isolated stem cells are induced at a specific cultivation generation (3rd-7th generation, and 10th generation) by specific small molecule pyrimidine compounds and a specific concentration (100[mu]M). The in vitro induction directional differentiation scheme of the isolated stem cells has another feature of promoting cell proliferation and phenotype expression of cardiac myocytes by the use of bFGF. The method provides a supplementary source for injured cardiac myocytes, establishes a foundation for replacing clinical treatment of myocardial infarction and later period heart failure by stem cell transplantation, and has good prospects for clinical application.

The invention relates to application of chrysin in in-vitro expansion of human hematopoietic stem cells. In the application, the concentration of chrysin in an amplification culture medium is 1-10 [mu]M. The invention also provides a human hematopoietic stem cell amplification culture medium and a method for amplifying the human hematopoietic stem cells. The chrysin has a good promotion effect onself-renewal of the human hematopoietic stem cells, and a new method can be provided for clinical treatment in the future.

Provided herein is a synthetic polymer-based hydrogel for the self-renewal and expansion of human stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Also provided are methods of making and using the same.

The present invention proposes a purpose of a reagent in preparing medicines, the medicine is used for the treatment of liver cancer, and the reagent is used for inhibiting the expression of MCM7 protein. The MCM7 protein is involved in the regulation of self-renewal of the liver cancer stem cells, by inhibiting the expression of the MCM7 protein, the self-renewal of the liver cancer stem cells can be inhibited, and a purpose of treating liver cancer can be achieved.

Stem cells modified to express activated form of STAT3 by genetic modification or protein delivery, and stem cells co-cultured with cells expressing activated form of STAT3 exhibit increased ex-vivo expansion and enhanced in-vivo regeneration accompanied by net increase in stem cell self-renewal as compared to control group.

Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed.

The invention belongs to the technical field of medicines, relates to the novel medicinal application of the traditional Chinese medicinal preparation, namely, Bufalin, and in particular relates to applications of bufalin in preparing a preparation capable of realizing targeted inhibition on pancreatic cancer stem cells. The invention further provides a method for culturing Miapaca2 / GEM by adopting a serum-free suspension culture method, and thus the stem cell spheres with a high proportion are obtained. According to the scheme, from the aspect of tumor stem cells, the experiment shows that in the application of preparing the preparation capable of realizing targeted inhibition on pancreatic cancer stem cells of the traditional Chinese medicinal preparation, namely, Bufalin, the preparation can inhibit the self-renewal of the tumor stem cells, particularly, the preparation can inhibit the proportion of the tumor stem cells in the pancreatic cancer drug resistant cell line Miapaca2 / GEM, and thus the drug tolerance of pancreatic cancer is inverted.

The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.

The invention relates to a modified Bach1 gene and an application thereof to pluripotency, self-updating, proliferation, reprogramming and differentiation of a stem cell. Due to the modification of the Bach1 gene of a transcription factor, the BACH1 protein activity or expression of the cell is inhibited or increased, and furthermore, the cell interacts with a deubiquitinated protease Usp7, a pluripotent factor Nanog, Sox2 and / or Oct4, a PRC2 complex, a Wnt / beta-catenin signal channel and / or an Nodal / Smad2 / 3 signal channel, so that the self-updating, proliferation and / or differentiation of thestem cell are regulated.

The invention belongs to the field of detection, and particularly relates to a serum-free medium capable of amplifying mesenchymal stem cells and a preparation method thereof. The serum-free medium mainly contains curcumin, cepharanthine, berberine, resveratrol, anthocyanidin, bone morphological protein 4, beta-glycerophosphate, cholesterol, isobutyl methyl xanthine, EGF, biotin, aFGF, heparin sodium, reduced glutathione, transferrin, insulin, ascorbic acid, dexamethasone, interleukin 2, vitamin B12, interleukin 6, stem cell factors, nicotinamide, TGF-beta 3, thrombopoietin, taurine, rosiglitazone, FMS-like tyrosine kinase 3 ligand, IGF2, sodium pyruvate, GM-CSF, TPO and the like. The serum-free culture medium not only has the capacity of amplifying mesenchymal stem cells derived from fat, placenta, bone marrow and umbilical cord in vitro, but also can maintain self-renewal of the stem cells, prevent differentiation of the stem cells and inhibit canceration of the stem cells.

The invention belongs to the field of traditional Chinese medicine detection and particularly relates to a serum-free culture medium capable of proliferating hematopoietic stem cells and a preparationmethod of the culture medium. The provided serum-free culture medium capable of proliferating hematopoietic stem cells comprises stephanine, berberine, bFGF, aFGF, IGF1, IGF2, transferrin, insulin growth factors, EGF, interleukin 1, interleukin 2, interleukin 6, stem cell factors, thrombopoietin, fMS-like tyrosine kinase 3 ligands and a DMEM / F12 culture medium. By adding stephanine and berberine,the serum-free culture medium not only has the capability of proliferating the hematopoietic stem cells derived from placentae, bone marrow and peripheral blood in vitro, improving the adherence capability of the hematopoietic stem cells and increasing the cell proliferation rate of the hematopoietic stem cells but also can maintain the self-renewal capability and multidirectional differentiationcapability of the stem cells. The hematopoietic stem cells proliferated by the serum-free culture medium have a good effect of promoting the reconstruction of a hematopoietic system in the body of apatient.

A human embryonic stem cell culture medium LD-1 independent to feeder cell (fibroblast or others) features that it contains some growth factor, such as fibre growth factor 2 (bFGF) and Noggin, which can support the self updating of human embryonic stem cells.

Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed.

The invention relates to application of levistilide A in preparation of a medicine for in-vitro amplification of human hematopoietic stem cells, in particular to application, in the application, the concentration of the levistilide A in an amplification culture medium is 1-10 [mu]M, and more preferably, the concentration of the levistilide A in the amplification culture medium is 5-10 [mu]M. The levistilactone A and the structure thereof have a good promotion effect on self-renewal of human hematopoietic stem cells, and a new method can be provided for clinical treatment in the future.

The invention discloses a demethylation-based vector for promoting self-renewal and proliferation of germline stem cells and application thereof. The vector is coated in slow virus, and carries mTet1 gene. The vector is a slow virus vector, and the nucleotide sequence of the mTet1 gene is disclosed as SEQ.ID.NO.1. After the vector disclosed by the invention is exprssed through the slow virus, the mTet1 gene is integrated to the genome of the milk goat male germline stem cells. When the stable positive cells are cultured, the cells grow in a swirl cluster mode and have favorable cytomorphology; the stream-mode analysis on the cell division cycle detects that the quantity of S-stage cells is increased, which indicates that the proliferation capacity is enhanced; and the transcription level detects that the expression of the male germline stem cell related gene and self-renewal related gene is increased, and the expression of the differentiation related gene is decreased.

The purpose of the present invention is to provide a method for inducing and inducing the differentiation into dopaminergic nerve cells in vitro after a large amount of neural stem cells are expanded, transplanting them in the striatum of the brain, and differentiating them into dopaminergic nerve cells in situ. In order to achieve the above object, the present invention adopts the following technical solutions: 1) Utilize the biology of stem cells to enrich neural stem cells by adopting the method of serum-free culture, utilize the self-renewal and proliferation characteristics of stem cells to amplify the neural stem cells with mitogenic proliferative factors , so as to achieve the purpose of obtaining a large number of neural stem cells. 2) The scheme of directional induction and differentiation of isolated cells in vitro, characterized in that specific culture passages (3-5 generation cells) are used for induction, and specific drug ascorbic acid is used for directional induction at a specific concentration (10-100nM); 3 ) in vivo directed differentiation of cells cultured, which is characterized in that a large number of neural stem cells obtained are differentiated into dopaminergic neurons in situ in the striatum of the brain by using a specific cell density and injection method. The invention provides a supplementary source after the nerve cells are lost, lays the foundation for the stem cell transplantation to replace clinical treatment of Parkinson's disease, and provides a new model for the development and screening of related drugs.

The invention proposes the application of the reagent in the preparation of medicine, the medicine is used for treating liver cancer, and the reagent is used for inhibiting the expression of MCM7 protein. The MCM7 protein is involved in the regulation of the self-renewal of the liver cancer stem cells, and by inhibiting the expression of the MCM7 protein, the self-renewal of the liver cancer stem cells can be inhibited, thereby achieving the purpose of treating liver cancer.

The invention discloses a compound formula for relieving testis senescence injury by comprehensively correcting cell reactive oxygen species (ROS) metabolic disorders. The compound formula comprises the following main components: melatonin (0.5-3mg / d), lipoic acid (50-500mg / d) and nicotinamide ribose (50-700mg / d). The components in the formula have clever metabolic synergy: the nicotinamide ribosepromotes generation of a main carrier of reduction potential and free energy, so that the lipoic acid is used as a redox switch to fully eliminate ROS damage of testicular cells; NADPH oxidase generated by nicotinamide ribose metabolism is catalyzed to generate second messenger ROS for maintaining self-renewal of testicular spermatogonial stem cells, and side effects can be ingeniously avoided when the lipoic acid and the melatonin eliminate ROS and interfere spermatogenesis. According to the formula, a high-flux standard cell experiment and a random double-blind control multi-center volunteer experiment are utilized to accurately ascertain the effects and toxicity threshold values of the components of the formula, so that the use dosages of the components have extremely high tolerance and safety, and the formula is suitable for being used as a core formula for development of related products.

The invention discloses the application of a T1 peptide in promoting the proliferation of umbilical cord blood hematopoietic stem cells in vitro. The present invention cultivates CD34+ hematopoietic stem cells in human umbilical cord blood under serum-free conditions, and simultaneously tests the effect of T1 (GPANVET) on the in vitro expansion of human umbilical cord blood hematopoietic stem cells, and finds that T1 peptide has an effect on the self-proliferation of human umbilical cord blood hematopoietic stem cells. The update has a better promotion effect. The present invention also found that the combination medium of stem cell factor (SCF), thrombopoietin (TPO), FMS-like tyrosine kinase 3 ligand (FLT3-L), interleukin-6 (IL-6) and T1 peptide has the effect of promoting hematopoiesis Stem cell expansion and maintenance of the proportion of stem cells can also improve the differentiation potential of hematopoietic stem cells, which can provide a new method for clinical treatment in the future.

The invention discloses a method for regulating self-renewal and differentiation of neural stem cells, comprising the steps of inoculating neural stem cells onto the surfaces of solid-supported phospholipid membranes with different fluidity and conducting cultivating, so as to regulate proliferation of the neural stem cells and promote differentiation of the neural stem cells along different differentiation directions. By the method for regulating self-renewal and differentiation of neural stem cells provided by the present invention, effective regulation of self-renewal ability and directed differentiation ability of stem cells can be achieved.

The invention relates to a modified Bach1 gene and an application thereof to pluripotency, self-updating, proliferation, reprogramming and differentiation of a stem cell. Due to the modification of the Bach1 gene of a transcription factor, the BACH1 protein activity or expression of the cell is inhibited or increased, and furthermore, the cell interacts with a deubiquitinated protease Usp7, a pluripotent factor Nanog, Sox2 and / or Oct4, a PRC2 complex, a Wnt / beta-catenin signal channel and / or an Nodal / Smad2 / 3 signal channel, so that the self-updating, proliferation and / or differentiation of thestem cell are regulated.